SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain.

Please see additional Important Safety Information on following pages and Full Prescribing Information at TEPEZZAhcp.com.
TEPEZZA significantly decreased proptosis, one of the most disfiguring symptoms of TED\textsuperscript{1,2,5,6}

**TEPEZZA**

83% vs placebo

10% (Week 24)

- **Significantly greater proptosis response rate**

- **TEPEZZA** significantly decreased proptosis, one of the most disfiguring symptoms of TED\textsuperscript{1,2,5,6}

- **Proptosis responder rate** (primary endpoint; Study 2)\textsuperscript{1,2,7}

- **Average change from baseline in proptosis over 24 weeks** (secondary endpoint; Study 2)\textsuperscript{1}

- **SELECT IMPORTANT SAFETY INFORMATION**

  The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.

Please see additional Important Safety Information on following pages and Full Prescribing Information at TEPEZZAhcp.com.
TEPEZZA showed significantly higher response rate for proptosis reduction and improved inflammatory signs of TED (pain, redness, and swelling)\(^1\-^3\)

**See the TEPEZZA transformation\(^7\)**

<table>
<thead>
<tr>
<th>BASELINE</th>
<th>POST-TREATMENT (WEEK 24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proptosis: 25 mm</td>
<td>Proptosis: 21 mm</td>
</tr>
<tr>
<td>Diplopia: 3</td>
<td>Diplopia: 0</td>
</tr>
</tbody>
</table>

**Inflammatory signs and symptoms:**
- Spontaneous orbital pain
- Gaze-evoked orbital pain
- Eyelid swelling
- Eyelid erythema
- Conjunctival redness

**Inflammatory signs and symptoms:**
No inflammatory signs or symptoms

Patient treated with TEPEZZA in a clinical trial. Results shown are with no surgical intervention. Individual results may vary.

**TEPEZZA 78% vs placebo 7%**

(Study 2; Week 24)

Similar results were seen in Study 1: more patients were overall responders\(^8\) with TEPEZZA vs placebo at Week 24 (69% vs 20%).\(^3\)

**Durable proptosis response was demonstrated 51 weeks after the last infusion of TEPEZZA in Study 1**

- 53% of patients (16 of 30) who were proptosis responders at Week 24 maintained a ≥2-mm reduction from baseline at Week 72 (~1 year off treatment)\(^1\)

**SELECT IMPORTANT SAFETY INFORMATION**

**Warnings and Precautions (continued)**

**Hyperglycemia:** Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Please see additional Important Safety Information on following pages and Full Prescribing Information at TEPEZZAhcp.com.
SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions (continued)

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Please see additional Important Safety Information on following pages and Full Prescribing Information at TEPEZZAhcp.com.
TEPEZZA was generally well tolerated—most adverse events were mild or moderate, were manageable, and resolved during or after treatment\textsuperscript{1}

<table>
<thead>
<tr>
<th>ADVERSE REACTIONS</th>
<th>TEPEZZA N=84 n (%)</th>
<th>Placebo N=86 n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle spasms</td>
<td>21 (25%)</td>
<td>6 (7%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>14 (17%)</td>
<td>8 (9%)</td>
</tr>
<tr>
<td>Alopecia</td>
<td>11 (13%)</td>
<td>7 (8%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>10 (12%)</td>
<td>7 (8%)</td>
</tr>
<tr>
<td>Fatigue\textsuperscript{a}</td>
<td>10 (12%)</td>
<td>6 (7%)</td>
</tr>
<tr>
<td>Hyperglycemia\textsuperscript{b}</td>
<td>8 (10%)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>Hearing impairment\textsuperscript{c}</td>
<td>8 (10%)</td>
<td>0</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>7 (8%)</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>7 (8%)</td>
<td>6 (7%)</td>
</tr>
<tr>
<td>Dry skin</td>
<td>7 (8%)</td>
<td>0</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Fatigue includes asthenia.
\textsuperscript{b}Hyperglycemia includes blood glucose increase.
\textsuperscript{c}Hearing impairment includes deafness, eustachian tube dysfunction, hyperacusis, hypoacusis, and autophony.

There was a low rate of discontinuation

89% of patients completed treatment with TEPEZZA vs 93% with placebo\textsuperscript{1}

Please see Important Safety Information on following pages and Full Prescribing Information at TEPEZZAhcp.com.
TEPEZZA is given once every 3 weeks for a total of 8 infusions¹

Dosing and administration

- TEPEZZA is dosed according to the patient's actual weight¹
- Administer the diluted solution as an IV solution over 90 minutes for the first 2 infusions¹
- If well tolerated, the minimum time for subsequent infusions can be reduced to 60 minutes¹
  - If not well tolerated, the minimum time for subsequent infusions should remain at 90 minutes¹

Other considerations

- Educate and counsel females of reproductive potential about the need to use effective contraception prior to initiation, during treatment with TEPEZZA, and for 6 months after the last dose¹
- Patients' glucose levels should be monitored for hyperglycemic reactions¹
- Patients with preexisting diabetes or impaired glucose tolerance should be under appropriate glycemic control before receiving TEPEZZA¹

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.

Please see additional Important Safety Information on previous pages and Full Prescribing Information at TEPEZZAhcp.com.


TEPEZZA and the HORIZON logo are trademarks owned by or licensed to Horizon. © 2020 Horizon Therapeutics plc P-TEP-00406 05/20